Amyris Inc (AMRS): Suing This Synthetic Biology Pioneer Is Silly

Page 2 of 2

Cosan Limited(USA) (NYSE:CZZ) has expanded its joint venture Novvi as recently as March. Many industrial biotech companies have chased cheap feedstock sources for initial operations, which makes Brazil’s sugarcane an easy target. Similarly, sugar producers can diversify their businesses by investing in industrial biotech. Cosan Limited(USA) (NYSE:CZZ) is looking to steer production away from sugar (commodity) and ethanol and into higher-value lubricants and base chemicals with Amyris Inc (NASDAQ:AMRS)’ platform.

In recent months, Amyris has also courted Firmenich, Givaudan, and International Flavors & Fragrances Inc (NYSE:IFF) for (ahem) flavors and fragrances and expanded product development with Kuraray for polymers and plastics. To say that international manufacturing companies are excited about the company’s products is an understatement. It will take time for the company to get on sturdy financial footing, but I’m cautiously optimistic Amyris Inc (NASDAQ:AMRS) has a bright future ahead of it.

Foolish bottom line
It doesn’t look like management intentionally misled investors. Instead, the group likely underestimated the challenge of growing its yeast at commercial scale. It also doesn’t look very good for the investor to bring the lawsuit almost 16 months after the period that caused him or her so much financial pain. This is just a reminder of what can happen when you invest in a developmental-stage company in a nascent industry. My advice: Take a long-term approach, don’t lose sleep over pops and drops, and don’t bring about lawsuits over movements in share price that occur during a 10-month period.

The article Suing This Synthetic Biology Pioneer Is Silly originally appeared on Fool.com and is written by Maxx Chatsko.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool recommends Total SA (ADR).

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2